Galectin Therapeutics Inc. (GALT)

Price & Market Data

Price: $2.65

Daily Change: +$0.126 / 4.78%

Daily Range: $2.49 - $2.76

Market Cap: $164,642,240

Daily Volume: 302,679

Performance Metrics

1 Week: 9.32%

1 Month: 12.66%

3 Months: -11.64%

6 Months: -54.50%

1 Year: 100.0%

YTD: -38.57%

About Galectin Therapeutics Inc. (GALT)

Get insights into Galectin Therapeutics Inc. (GALT)'s financial health. With a price of 2.65, the stock shows a +$0.126 / 4.78% daily change. Its market cap is 164,642,240. Detailed performance for 1-month (12.66%) and 52-week (100.0%) periods are crucial.

Company Details

Employees: 9

Sector: Health technology

Industry: Biotechnology

Country: United States

Details

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Selected stocks

SS Innovations International Inc. (SSII)

Editas Medicine, Inc. (EDIT)

Raytech Holding Limited (RAY)

Mixed Martial Arts Group Limited (MMA)

MFS Municipal Income Trust (CMU)